BioLineRx BL-7010 may reduce gluten toxicity in sufferers with celiac disease BioLineRx , a biopharmaceutical advancement firm, announced the publication of pre-clinical outcomes demonstrating that BL-7010, an obtainable treatment for celiac disease orally, reduces gluten toxicity . The study was released in the February edition of Gastroenterology finasteride hair loss propeciafrance.net . The results indicate that BL-7010 ) decreases digestion of wheat gluten, decreasing its toxicity thereby. Furthermore, BL-7010 attenuates the immune response to gluten in rodents and helps prevent gluten-induced pathological harm to the tiny intestine.
Previous Post: Axis Three announces option of new XS-400 scanner for face.